Yin Zhengrong, Deng Jingjing, Zhou Mei, Li Minglei, Zhou E, Liu Jiatong, Jia Zhe, Yang Guanghai, Jin Yang
Department of Respiratory and Critical Care Medicine, Hubei Province Clinical Research Center for Major Respiratory Diseases, NHC Key Laboratory of Pulmonary Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, MOE Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Cancers (Basel). 2022 Oct 18;14(20):5106. doi: 10.3390/cancers14205106.
Lung adenocarcinoma (LUAD) is the primary histological subtype of lung cancer with a markedly heterogeneous prognosis. Therefore, there is an urgent need to identify optimal prognostic biomarkers. We aimed to explore the value of the circadian miRNA (cmiRNA) pair in predicting prognosis and guiding the treatment of LUAD. We first retrieved circadian genes (Cgenes) from the CGDB database, based on which cmiRNAs were predicted using the miRDB and mirDIP databases. The sequencing data of Cgenes and cmiRNAs were retrieved from TCGA and GEO databases. Two random cmiRNAs were matched to a single cmiRNA pair. Finally, univariate Cox proportional hazard analysis, LASSO regression, and multivariate Cox proportional hazard analysis were performed to develop a prognostic signature consisting of seven cmiRNA pairs. The signature exhibited good performance in predicting the overall and progression-free survival. Patients in the high-risk group also showed lower IC50 values for several common chemotherapy and targeted medicines. In addition, we constructed a cmiRNA-Cgenes network and performed a corresponding Gene Ontology and Gene Set enrichment analysis. In conclusion, the novel circadian-related miRNA pair signature could provide a precise prognostic evaluation with the potential capacity to guide individualized treatment regimens for LUAD.
肺腺癌（LUAD）是肺癌的主要组织学亚型，其预后存在明显的异质性。因此，迫切需要确定最佳的预后生物标志物。我们旨在探讨昼夜节律性微小RNA（cmiRNA）对在预测LUAD预后和指导治疗方面的价值。我们首先从CGDB数据库中检索昼夜节律基因（C基因），并基于此使用miRDB和mirDIP数据库预测cmiRNAs。从TCGA和GEO数据库中检索C基因和cmiRNAs的测序数据。将两个随机的cmiRNAs配对形成一个cmiRNA对。最后，进行单变量Cox比例风险分析、LASSO回归和多变量Cox比例风险分析，以构建一个由七个cmiRNA对组成的预后特征。该特征在预测总生存期和无进展生存期方面表现良好。高危组患者对几种常用化疗药物和靶向药物的IC50值也较低。此外，我们构建了一个cmiRNA-C基因网络，并进行了相应的基因本体论和基因集富集分析。总之，新的昼夜节律相关微小RNA对特征可为LUAD提供精确的预后评估，并具有指导个体化治疗方案的潜在能力。
